obeticholic acid 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
5155 459789-99-2

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • obeticholic acid
  • ocaliva
  • 6-ECDCA
  • 6ECDCA
  • INT-747
obeticholic acid is an agonist for FXR, a nuclear receptor expressed in the liver and intestine
  • Molecular weight: 420.63
  • Formula: C26H44O4
  • CLOGP: 5.36
  • LIPINSKI: 1
  • HAC: 4
  • HDO: 3
  • TPSA: 77.76
  • ALOGS: -4.58
  • ROTB: 5

  • Status: ONP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
10 mg O

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Dec. 12, 2016 EMA Intercept Pharma Ltd
May 27, 2016 FDA INTERCEPT PHARMACEUTICALS INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Pruritus 1495.21 28.22 644 3960 315979 55971484
Therapy cessation 249.60 28.22 91 4513 27173 56260290
Hospitalisation 203.28 28.22 106 4498 74894 56212569
Therapy interrupted 174.68 28.22 69 4535 25556 56261907
Product dose omission issue 165.04 28.22 135 4469 204618 56082845
Blood alkaline phosphatase abnormal 133.33 28.22 24 4580 395 56287068
Hepatic cirrhosis 103.34 28.22 45 4559 21218 56266245
Fatigue 92.89 28.22 200 4404 788352 55499111
Insurance issue 85.12 28.22 25 4579 3767 56283696
Blood alkaline phosphatase increased 80.21 28.22 46 4558 38899 56248564
Hepatic fibrosis 70.68 28.22 21 4583 3291 56284172
Emergency care 69.93 28.22 16 4588 900 56286563
Constipation 58.45 28.22 77 4527 201866 56085597
Portal hypertension 52.55 28.22 17 4587 3524 56283939
Varices oesophageal 51.56 28.22 16 4588 2900 56284563
Dry skin 46.19 28.22 35 4569 47074 56240389
Rehabilitation therapy 43.87 28.22 12 4592 1398 56286065
Therapy change 38.11 28.22 15 4589 5473 56281990
Death 34.58 28.22 82 4522 341344 55946119
Splenomegaly 32.17 28.22 16 4588 10152 56277311
Liver disorder 28.88 28.22 26 4578 44344 56243119

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Pruritus 166.37 42.25 57 264 125110 31571913
Hospitalisation 43.74 42.25 17 304 49790 31647233

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Pruritus 1311.92 33.35 521 3005 345039 70579879
Therapy cessation 182.47 33.35 67 3459 33609 70891309
Product dose omission issue 129.94 33.35 98 3428 217370 70707548
Therapy interrupted 114.78 33.35 44 3482 24758 70900160
Fatigue 91.36 33.35 153 3373 824166 70100752
Hepatic cirrhosis 89.08 33.35 39 3487 30692 70894226
Blood alkaline phosphatase abnormal 86.06 33.35 17 3509 783 70924135
Blood alkaline phosphatase increased 67.95 33.35 40 3486 58481 70866437
Hospitalisation 67.10 33.35 45 3481 82523 70842395
Insurance issue 55.84 33.35 16 3510 3645 70921273
Constipation 45.18 33.35 59 3467 252379 70672539
Varices oesophageal 41.61 33.35 14 3512 5403 70919515
Hepatic fibrosis 35.84 33.35 13 3513 6254 70918664

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC A05AA04 ALIMENTARY TRACT AND METABOLISM
BILE AND LIVER THERAPY
BILE THERAPY
Bile acids and derivatives
FDA MoA N0000192560 Farnesoid X Receptor Agonists
FDA EPC N0000192561 Farnesoid X Receptor Agonist
CHEBI has role CHEBI:62868 hepatoprotective agents
CHEBI has role CHEBI:132972 farnesoid X receptor agonists

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Primary cholangitis indication 17266006




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 4.92 acidic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
10MG OCALIVA INTERCEPT PHARMS INC N207999 May 27, 2016 RX TABLET ORAL 8058267 Feb. 21, 2022 TREATMENT OF PRIMARY BILIARY CHOLANGITIS (PBC)
10MG OCALIVA INTERCEPT PHARMS INC N207999 May 27, 2016 RX TABLET ORAL 8377916 Feb. 21, 2022 TREATMENT OF PRIMARY BILIARY CHOLANGITIS (PBC)
5MG OCALIVA INTERCEPT PHARMS INC N207999 May 27, 2016 RX TABLET ORAL 8058267 Feb. 21, 2022 TREATMENT OF PRIMARY BILIARY CHOLANGITIS (PBC)
5MG OCALIVA INTERCEPT PHARMS INC N207999 May 27, 2016 RX TABLET ORAL 8377916 Feb. 21, 2022 TREATMENT OF PRIMARY BILIARY CHOLANGITIS (PBC)
10MG OCALIVA INTERCEPT PHARMS INC N207999 May 27, 2016 RX TABLET ORAL 10047117 Sept. 6, 2033 TREATMENT OF PRIMARY BILIARY CHOLANGITIS (PBC)
5MG OCALIVA INTERCEPT PHARMS INC N207999 May 27, 2016 RX TABLET ORAL 10047117 Sept. 6, 2033 TREATMENT OF PRIMARY BILIARY CHOLANGITIS (PBC)
10MG OCALIVA INTERCEPT PHARMS INC N207999 May 27, 2016 RX TABLET ORAL 10758549 April 26, 2036 TREATMENT OF PRIMARY BILIARY CHOLANGITIS (PBC) IN COMBINATION WITH URSODEOXYCHOLIC ACID (UDCA) IN ADULTS WITH AN INADEQUATE RESPONSE TO UDCA, OR AS MONOTHERAPY IN ADULTS UNABLE TO TOLERATE UDCA
5MG OCALIVA INTERCEPT PHARMS INC N207999 May 27, 2016 RX TABLET ORAL 10758549 April 26, 2036 TREATMENT OF PRIMARY BILIARY CHOLANGITIS (PBC) IN COMBINATION WITH URSODEOXYCHOLIC ACID (UDCA) IN ADULTS WITH AN INADEQUATE RESPONSE TO UDCA, OR AS MONOTHERAPY IN ADULTS UNABLE TO TOLERATE UDCA

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
10MG OCALIVA INTERCEPT PHARMS INC N207999 May 27, 2016 RX TABLET ORAL May 27, 2023 TREATMENT OF PRIMARY BILIARY CHOLANGITIS (PBC) IN COMBINATION WITH URSODEOXYCHOLIC ACID (UDCA) IN ADULTS WITH AN INADEQUATE RESPONSE TO UDCA, OR AS MONOTHERAPY IN ADULTS UNABLE TO TOLERATE UDCA
5MG OCALIVA INTERCEPT PHARMS INC N207999 May 27, 2016 RX TABLET ORAL May 27, 2023 TREATMENT OF PRIMARY BILIARY CHOLANGITIS (PBC) IN COMBINATION WITH URSODEOXYCHOLIC ACID (UDCA) IN ADULTS WITH AN INADEQUATE RESPONSE TO UDCA, OR AS MONOTHERAPY IN ADULTS UNABLE TO TOLERATE UDCA

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Bile acid receptor Nuclear hormone receptor AGONIST EC50 7.00 SCIENTIFIC LITERATURE DRUG LABEL
G-protein coupled bile acid receptor 1 GPCR EC50 7 CHEMBL

External reference:

IDSource
0462Z4S4OZ UNII
C1143018 UMLSCUI
CHEBI:43602 CHEBI
CHEMBL566315 ChEMBL_ID
D09360 KEGG_DRUG
447715 PUBCHEM_CID
DB05990 DRUGBANK_ID
9084 INN_ID
3435 IUPHAR_LIGAND_ID
1798288 RXNORM
241391 MMSL
31698 MMSL
d08442 MMSL
016875 NDDF
720257002 SNOMEDCT_US
763557003 SNOMEDCT_US
4035786 VANDF
CHC PDB_CHEM_ID
IU6 PDB_CHEM_ID
C464660 MESH_SUPPLEMENTAL_RECORD_UI

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Ocaliva HUMAN PRESCRIPTION DRUG LABEL 1 69516-005 TABLET, FILM COATED 5 mg ORAL NDA 32 sections
Ocaliva HUMAN PRESCRIPTION DRUG LABEL 1 69516-005 TABLET, FILM COATED 5 mg ORAL NDA 32 sections
Ocaliva HUMAN PRESCRIPTION DRUG LABEL 1 69516-005 TABLET, FILM COATED 5 mg ORAL NDA 32 sections
Ocaliva HUMAN PRESCRIPTION DRUG LABEL 1 69516-010 TABLET, FILM COATED 10 mg ORAL NDA 32 sections
Ocaliva HUMAN PRESCRIPTION DRUG LABEL 1 69516-010 TABLET, FILM COATED 10 mg ORAL NDA 32 sections
Ocaliva HUMAN PRESCRIPTION DRUG LABEL 1 69516-010 TABLET, FILM COATED 10 mg ORAL NDA 32 sections